Ranbaxy Recalls Nearly 30,000 Packs of Allergy-relief Drug in U.S
May 3, 2014 2:14 PM EST
Drugmaker Ranbaxy Laboratories Ltd (RANB.NS) started recalling 29,790 packs of an allergy-relief medicine in the United States in February, after finding defects in the packaging, the U.S. Food and Drug Administration said.
Sun Pharma to Buy Ranbaxy in $3.2 Billion all-share Deal
The loratadine and pseudoephedrine sulphate extended release tablets being recalled carry an expiry date of September 2015, and were manufactured by Ranbaxy's Ohm Labs plant in New Jersey, which is the company's only facility making generics for the United States.
All other Ranbaxy plants, based in India, have been banned from exporting generics to the United States after the FDA found manufacturing quality glitches that the agency believed could compromise the quality of medicines.
The FDA classified the recall by Ohm Labs as Class II, which means use of or exposure to the recalled products may cause temporary or medically reversible adverse health consequences.
Ranbaxy did not immediately respond to requests for comment.
Join the Conversation
- Unruly Female Passenger Who Assaults FA Forces Air Canada To Divert Flight
- Apple iPhone 6 Is Not Behind Samsung’s Downfall, The Real Achilles' Heel Is Xiaomi--Reports
- Instagram Rolls Out Five New Filters Including Aden, Crema, Ludwig, Perpetua And Slumber For Better Photos [WATCH VIDEO]
- Tariff Cuts Underway With Japan-Australia Economic Partnership